Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

After avandia: the use of antidiabetic drugs in patients with heart failure.

Khalaf KI, Taegtmeyer H.

Tex Heart Inst J. 2012;39(2):174-8. Review.

2.

Glucose supply and insulin demand dynamics of antidiabetic agents.

Monte SV, Schentag JJ, Adelman MH, Paladino JA.

J Diabetes Sci Technol. 2010 Mar 1;4(2):365-81.

3.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
4.

The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies.

Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, Romio S, Perez-Gutthann S.

BMC Cardiovasc Disord. 2014 Sep 26;14:129. doi: 10.1186/1471-2261-14-129. Review.

6.

A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.

Seufert J, Lübben G, Dietrich K, Bates PC.

Clin Ther. 2004 Jun;26(6):805-18. Review.

PMID:
15262452
7.
8.

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association.

Circulation. 2003 Dec 9;108(23):2941-8. Review. No abstract available.

9.

A clinical trial to maintain glycemic control in youth with type 2 diabetes.

TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F.

N Engl J Med. 2012 Jun 14;366(24):2247-56. doi: 10.1056/NEJMoa1109333. Epub 2012 Apr 29.

10.

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Fonseca V, Rosenstock J, Patwardhan R, Salzman A.

JAMA. 2000 Apr 5;283(13):1695-702. Erratum in: JAMA 2000 Sep 20;284(11):1384.

PMID:
10755495
11.

Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.

Strowig SM, Raskin P.

Diabetes Obes Metab. 2005 Nov;7(6):633-41. Review.

PMID:
16219007
12.

Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.

Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.

Pharmacotherapy. 2006 Feb;26(2):168-81. Review.

PMID:
16466323
13.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

14.

[Medication of the month. Rosiglitazone (Avandia)].

Scheen AJ.

Rev Med Liege. 2002 Apr;57(4):236-9. Review. French.

15.

Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators.

Circulation. 2013 Aug 20;128(8):785-94. doi: 10.1161/CIRCULATIONAHA.112.000678. Epub 2013 Jul 15.

16.

Type 2 diabetes mellitus and heart failure.

Choy CK, Rodgers JE, Nappi JM, Haines ST.

Pharmacotherapy. 2008 Feb;28(2):170-92. doi: 10.1592/phco.28.2.170. Review.

PMID:
18225964
17.

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.

Diabetes Obes Metab. 2009 Jan;11(1):27-32. Epub 2007 Oct 17.

PMID:
17941873
18.

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V; ECLA Study Group.

Cardiovasc Diabetol. 2011 Feb 11;10:18. doi: 10.1186/1475-2840-10-18.

19.

Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M.

Circulation. 2009 Apr 21;119(15):2069-77. doi: 10.1161/CIRCULATIONAHA.108.803916. Epub 2009 Apr 6.

20.

Supplemental Content

Support Center